Health Condition 1: E08-E13- Diabetes mellitus
Conditions
Interventions
Intervention1: GROUP A - DAPAGLIFLOZIN: DRUG NAME - DAPAGLIFLOZIN
DOSE - 10 MG
ROUTE - PER ORAL
FREQUENCY - ONCE A DAY FOR TOTAL DURATION OF 6 WEEKS
Intervention2: GROUP B - DAPAGLIFLOZIN AND EPLERENO
Sponsors
Dr Nikhil Kumar
Eligibility
Inclusion criteria
Inclusion criteria: b)Patients having urinary albumin to creatinine ratio (UACR) more than >30mg/mmol.
Exclusion criteria
Exclusion criteria: a)Failure to give consent b)History of serious reactions to dapagliflozin and eplerenone c)Severe renal impairment (eGfr less than 30/ml/min/1.73m2 d)End-stage renal disease (ESRD) e)Patient on dialysis f)Patient having serum potassium >5.5meq/l at initiation g)Concomitant administration of strong cyp3a inhibitors (e.g. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir and nelfinavir h)Concomitant administration of potassium supplements or potassium-sparing diuretics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| URINE ALBUMIN TO CREATININE RATIOTimepoint: BASELINE, 6 WEEKS | — |
Secondary
| Measure | Time frame |
|---|---|
| SERUM CREATININETimepoint: AT 0, 6 weeks | — |
Countries
India
Contacts
Public ContactNIKHIL Kumar
Dr. Rajendra Prasad Govt. Medical College & Hospital Tanda H.P.
Outcome results
None listed